Pricing and Reimbursement Issues in Psychiatry

Compared with many other disease areas (e.g., cancer, immune diseases), the costs of drug therapy for psychiatric disorders are relatively modest. However, the World Health Organization forecasts that by 2020, depression-just one of a spectrum of psychiatric disorders-will be the second most frequent cause of death and disability in the world and the leading cause in industrialized nations. In anticipation of this surge, payers in the major pharmaceutical markets would like to exercise greater control over the use of psychiatric drugs. Get the Answers You Need to Shape Your Strategy In just the major pharmaceutical markets, the number of people afflicted with common psychiatric disorders will increase, and spending on drug therapies will grow steadily. How will payers try to curb spending on psychiatric drugs? The prices of generic antidepressants are much higher in Europe than in the United States. What factors are behind this differential? Pharmacy benefits offered by U.S. private insurers tend to be considerably more generous than the coverage provided by Medicare and Medicaid, but cost-containment measures are proliferating. What steps are private insurers taking to control drug expenditures? Medicare Part D offers outpatient drug coverage to all Medicare beneficiaries who choose to enroll. What will be the standard benefi t design of Part D in 2007? The U.S. Medicaid program is a major source of funding for psychiatric drugs-especially atypical antipsychotics. What cost-cutting measures are state Medicaid programs instituting to control drug expenditures? France has the lowest average prices of any of the major pharmaceutical markets for branded antidepressants. Nevertheless, the government would like to reduce spending on this drug class. What steps has the Caisse Nationale de l'Assurance Maladie taken to stimulate France's relatively immature generics market? How successful have these measures been so far? Scope Drug classes covered: antidepressants, antipsychotics, psychostimulants, hypnotics, sedatives, and anxiolytics. Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan. Price comparisons: comparisons of international pricing of the psychiatric drug classes in this report. Reimbursement: overview of the general environment in each market and analysis of factors specifi c to individual psychiatric drug classes. Market outlook: pricing and reimbursement implications for the manufacturers of psychiatric drugs.Please note, the PDF e-mail from publisher version of this report is for a global site license.

Additional Information


Mentioned in This Spectrum Report
Companies

AstraZeneca
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Johnson & Johnson
Pfi zer
Sanofi -Aventis
Sepracor
Wyeth

Organizations

Bundesverband der Betriebskrankenkassen
(Federal Association of Occupational
Health Insurance Funds), Germany
Caisse Nationale de l’Assurance Maladie
(National Health Insurance Fund), France
Centers for Medicare and Medicaid
Services, United States
Commission de la Transparence
(Transparency Commission), France
Department of Health and Human
Services, United States
Gesetzliche Krankenversicherung (Statutory
Health Insurance System), Germany
Kaiser Commission on Medicaid and the
Uninsured, United States
Kassenärztliche Bundesvereinigung
(Federal Union of Health Insurance Fund
Physicians), Germany
Medicaid, United States
Medicare, United States
Ministry of Health, Labor, and Welfare,
Japan
National Health Insurance, Japan
National Health Service, United Kingdom
National Institute for Health and Clinical
Excellence (NICE), United Kingdom
Pharmaceutical Research and
Manufacturers of America
Prontuario Nazionale Farmaceutico
(National Formulary), Italy
Scottish Intercollegiate Guidelines
Network
Scottish Medicines Consortium
Servizio Sanitario Nazionale (National
Health Service), Italy
Sistema Nacional de Salud (National Health
System), Spain
U.S. Pharmacopeial Convention
World Health Organization